Peter Ballard
AstraZeneca, Alderley Park
Macclesfield, ENG, United Kingdom
Macclesfield, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Absence of developmental and reproductive toxicity in rats, rabbits, and zebrafish embryos exposed to antimalarial drug cabamiquine.
Journal: Birth defects research
Published: April 16, 2024
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 16, 2017
Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.
Journal: Molecular cancer therapeutics
Published: March 17, 2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2016
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: December 23, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Journal: Journal of medicinal chemistry
Published: September 26, 2015
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Journal: Cancer research
Published: August 28, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
Journal: Journal of medicinal chemistry
Published: March 05, 2015
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
Journal: Journal of medicinal chemistry
Published: October 02, 2014
Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: July 10, 2014
Last Updated: 09/26/2026